[HTML][HTML] Targeting PI3K/AKT/mTOR signaling pathway as a radiosensitization in head and neck squamous cell carcinomas
YC Su, WC Lee, CC Wang, SA Yeh, WH Chen… - International Journal of …, 2022 - mdpi.com
Globally, there are over half a million new patients with head and neck squamous cell
carcinomas (HNSCC) every year. The current therapeutic approaches to HNSCC are …
carcinomas (HNSCC) every year. The current therapeutic approaches to HNSCC are …
[HTML][HTML] Advancements of radiotherapy for recurrent head and neck cancer in modern era
S Zhang, N Zeng, J Yang, J He, F Zhu, W Liao… - Radiation …, 2023 - Springer
Head and neck cancer is a kind of cancer which can be eradicated from radical radiation
therapy. However, with best efforts, nearly 40% patients will experience locoregional …
therapy. However, with best efforts, nearly 40% patients will experience locoregional …
[HTML][HTML] PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy
FC Chuang, CC Wang, JH Chen, TZ Hwang, SA Yeh… - PLoS …, 2021 - journals.plos.org
Approximately 500,000 new cases of head and neck squamous cell carcinoma (HNSCC)
are reported annually. Radiation therapy is an important treatment for oral squamous cell …
are reported annually. Radiation therapy is an important treatment for oral squamous cell …
[HTML][HTML] Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety
Background The objective of this study was to compare the efficacy and safety of taxane
(docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) with cisplatin plus fluorouracil …
(docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) with cisplatin plus fluorouracil …
Predicting survival after irradiation for brain metastases from head and neck cancer
D Rades, L Dziggel, SG Hakim, V Rudat, S Janssen… - In Vivo, 2015 - iv.iiarjournals.org
Aim: Patients with cerebral metastases from head and neck cancer are not common. This
study aimed to create an instrument for estimating survival in this particular group of patients …
study aimed to create an instrument for estimating survival in this particular group of patients …
Synergistic effect of honokiol and 5‐fluorouracil on apoptosis of oral squamous cell carcinoma cells
Background 5‐Fluorouracil (5‐FU) is an essential chemotherapeutic agent for oral
squamous cell carcinoma (OSCC). However, toxic side effects have limited its role in OSCC …
squamous cell carcinoma (OSCC). However, toxic side effects have limited its role in OSCC …
The oncological outcome and influence of neoadjuvant chemotherapy on the surgery in the resectable and locally advanced oral squamous cell carcinoma
X Su, Q Liu, J Li, C Zhang, Z Xue, C He… - Cancer Management …, 2019 - Taylor & Francis
Aim The role of neoadjuvant chemotherapy (NCT) in the treatment of advanced oral
squamous cell carcinoma (OSCC) is still controversial. Especially, there are still few studies …
squamous cell carcinoma (OSCC) is still controversial. Especially, there are still few studies …
[PDF][PDF] Snail-induced CD44high cells in HNSCC with high ABC transporter capacity exhibit potent resistance to cisplatin and docetaxel
M Hashikata, H Shigeishi, G Okui, K Yamamoto… - Int J Clin Exp …, 2016 - e-century.us
CD44high head and neck squamous cell carcinoma (HNSCC) cells with cancer stem cell
(CSC)-like properties have been speculated to be involved in resistance to apoptosis …
(CSC)-like properties have been speculated to be involved in resistance to apoptosis …
[PDF][PDF] Role of Neoadjuvant Chemotherapy in Oral Cavity SCC: A Surgical Oncologists Experience at Tertiary Care Institute
D Patel, E Saldanha, B Joseph, S Ghosh… - European Journal of …, 2021 - researchgate.net
Abstract Oral Squamous Cell Carcinoma (OSCC) is a common malignant head and neck
tumor. The mainstay treatment of OSCC is surgery-centered multimodality therapy …
tumor. The mainstay treatment of OSCC is surgery-centered multimodality therapy …
[PDF][PDF] 选择性动脉灌注化疗在口腔癌治疗中的进展
黄桂林 - Journal of Oral and Maxillofacial Surgery, 2015 - journal06.magtech.org.cn
选择性动脉灌注化疗在口腔癌治疗中的进展 Page 1 专家论坛 选择性动脉灌注化疗在口腔癌治疗
中的进展 黄桂林 (遵义医学院附属口腔医院口腔颂面外科r头颈肿瘤治疗组,贵州遵义563000) [摘要 …
中的进展 黄桂林 (遵义医学院附属口腔医院口腔颂面外科r头颈肿瘤治疗组,贵州遵义563000) [摘要 …